Importance of a history of hypertension for the prognosis after acute myocardial infarction - For the Bucindolol Evaluation in Acute Myocardial Infarction Trial (BEAT) Study Group

Clinical Cardiology

Volumn 27, Issue 5, 2004, Pages 265-269

  Ali, Irma ^a   Akman, Dilek ^b   Bruun, Niels Eske ^a   Køber, Lars ^b   Brendorp, Bente ^a   Ottesen, Michael ^a   Møller, Jacob ^a   Torp Pedersen, Christian ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Angiotensin converting enzyme inhibitor; Beta blocker; Hypertension; Myocardial infarction; Survival

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ACUTE HEART INFARCTION; AGE; ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; PAST MEDICAL HISTORY; PROGNOSIS; REGISTER; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

EID: 2542534516     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960270504     Document Type: Article

References (27)

1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003
2. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-1010
3. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587
4. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581
5. Torp-Pedersen C, Kober L: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;354:9-12
6. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-2212
7. Fresco C, Avanzini F, Bosi S, Franzosi MG, Maggioni AP, Santoro L, Bellanti G: Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Hypertens 1996;14:743-750
8. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzosi MG, Geraci E, Maggioni AP, Marfisi RM, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Valagussa F: Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001;22:2085-2103
9. Kornowski R, Goldbourt U, Boyko V, Behar S: Clinical predictors of reinfarction among men and women after a first myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Cardiology 1995;86:163-168
10. Herlitz J, Bang A, Karlson BW: Five-year prognosis after acute myocardial infarction in relation to a history of hypertension. Am J Hypertens 1996;9:70-76
11. Gustafsson F, Kober L, Torp-Pedersen C, Hildebrandt P, Ottesen MM, Sonne B, Carlsen J: Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension. TRACE study group. Eur Heart J 1998;19:588-594
12. Gustafsson F, Torp-Pedersen C, Kober L, Hildebrandt P: Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. J Hypertens 1997;15:793-798
13. Torp-Pedersen C, Kober L, Ball S, Hall A, Brendorp B, Ottesen M, Berning J, Jensen G, Hampton J, Zilles P, Eberle S, Carlsen J: The incomplete Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT). Eur J Heart Fail 2002;4:495-499
14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367
15. Berning J, Steensgaard-Hansen F: Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol 1990;65:567-576
16. Berning J, Rokkedal Nielsen J, Launbjerg J, Fogh J, Mickley H, Andersen PE: Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology 1992;80:257-266
17. The Euroaspire II Investigators: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572
18. Spargias K, Ball S, Hall A: The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: Evidence from the AIRE study. Acute Infarction Ramipril Efficacy. J Hum Hypertens 1999;13:511-516
19. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E: Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999;12:665-672
20. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, MacMahon S: Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995;92:2437-2445
21. van den Hoogen PC, van Popele NM, Feskens EJ, van der Kuip DA, Grobbee DE, Hofman A, Witteman JC: Blood pressure and risk of myocardial infarction in elderly men and women: The Rotterdam study. J Hypertens 1999;17:1373-1378
22. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-1249
23. Kannel WB: Blood pressure as a cardiovascular risk factor: Prevention and treatment. J Am Med Assoc 1996;275:1571-1576
24. Moser M, Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-1218
25. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. J Am Med Assoc 1997;278:212-216
26. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-1390
27. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. J Am Med Assoc 1998;279:1903-1907